ESCHERICHIA COLI CAPABLE OF PRODUCING 3-AMINO-4-HYDROXYBENZOIC ACID |
|||||||
| 申请号 | EP13754464.9 | 申请日 | 2013-01-28 | 公开(公告)号 | EP2821479A1 | 公开(公告)日 | 2015-01-07 |
| 申请人 | Ajinomoto Co., Inc.; | 发明人 | SHOZUI, Fumi; TAJIMA, Yoshinori; | ||||
| 摘要 | The present invention provides a method for conveniently and inexpensively producing an amino-hydroxybenzoic acid-type compound such as 3-amino-4-hydroxybenzoic acid by utilizing Escherichia coli that is a bacterium commonly used for a production process by biosynthesis. Specifically, the present invention provides Escherichia coli having an ability to produce 3-amino-4-hydroxybenzoic acid, which is modified to reduce an activity of N-hydroxyarylamine O-acetyltransferase (NhoA); a method for producing a 3-amino-4-hydroxybenzoic acid-type compound using such Escherichia coli; and the like. | ||||||
| 权利要求 | |||||||
| 说明书全文 | The present invention relates to Escherichia coli having an ability to produce 3-amino-4-hydroxybenzoic acid and a method for producing an amino-hydroxybenzoic acid-type compound using the same. An amino-hydroxybenzoic acid-type compound is useful as an intermediate of dyes, agricultural chemicals, pharmaceuticals and other synthesized organic products and as a monomer of a sophisticated and heat resistant polymer, polybenzoxazole. 3-Amino-4-hydroxybenzoic acid (3,4-AHBA) is biosynthesized in two steps by both GriI that is an enzyme catalyzing a carbon-carbon binding reaction between a C4 compound having an amino group and a C3 or C4 compound and GriH that is an enzyme catalyzing cyclization of a C7 compound or cyclization of a C8 compound with decarboxylation, using dihydroxyacetone phosphate (DHAP) and aspartate semialdehyde (ASA) as substrates. The followings are available as prior art related to the present invention. In Patent Literature 1, a method for producing 3,4-AHBA using Streptomyces griseus in which griI and griH were introduced has been disclosed. Patent Literature 1 has also disclosed that 3-acetylamino-4-hydroxybenzoic acid (3,4-AcAHBA) which is a byproduct of 3,4-AHBA is formed and that 3,4-AcAHBA is deacetylated to form 3,4-AHBA. Use of a strong base such as sodium hydroxide and a strong acid such as hydrochloric acid is exemplified as a specific method of deacetylating 3,4-AcAHBA. However, such method has a problem that the strong base and the strong acid have to be used. In Patent Literature 2, it has been disclosed that 3,4-AHBA is formed by the use of Corynebacterium glutamicum in which griI and griH were introduced. In Non-patent Literature 1, it has been disclosed that 3,4-AHBA and 3,4-AcAHBA are formed by introducing griI and griH into Escherichia coli. In Non-patent Literature 2, it has been disclosed that when an arylamine N-acetyltransferase gene (natA) is deleted in Streptomyces griseus, 3,4-AcAHBA is not formed in culture. In Non-patent Literature 3, it has been disclosed that an N-hydroxyarylamine O-acetyltransferase gene (nhoA) derived from Escherichia coli works to catalyze the acetylation of an aromatic amino group. Meanwhile, in Non-patent Literature 4, it has been disclosed that Escherichia coli BAP1 strain forms an N-acetylated form (3,5-AcAHBA) as a byproduct of 3,5-AHBA (structural isomer of 3,4-AHBA), 3,5-AcAHBA is also produced as the byproduct in an nhoA gene-deleted strain (MAR1 strain) of Escherichia coli BAP1, and thus, the NhoA does not appear to be a major factor for N-acetylation of 3,5-AHBA.
This invention has been made in the light of actual circumstance of such prior art technology, and it is an object of the present invention to provide a method for conveniently and inexpensively producing an aminohydroxybenzoic acid-type compound such as 3-amino-4-hydroxybenzoic acid by utilizing Escherichia coli that is a bacterium commonly used for production processes by biosynthesis methods. As a result of an extensive study, the present inventors have found that nhoA is involved in formation of 3,4-AcAHBA as a byproduct from 3,4-AHBA in Escherichia coli and thus 3,4-AHBA which is not acetylated can be produced in large amounts by the use of Escherichia coli modified to reduce an NhoA activity, and have completed the present invention. That is, the present invention is as follows.
According to the present invention, the aminohydroxybenzoic acid-type compound such as 3-amino-4-hydroxybenzoic acid can be produced conveniently and inexpensively. The present invention provides Escherichia coli that is a bacterium having an ability to produce 3-amino-4-hydroxybenzoic acid. Formation of an acetylated byproduct (3,4-AcAHBA) can be inhibited in the bacterium of the present invention. In the bacterium of the present invention, the formation of the acetylated byproduct can be inhibited by modifying the bacterium to reduce the activity of N-hydroxyarylamine O-acetyltransferase (NhoA). The NhoA activity is an N-hydroxyarylamine O-acetyltransferase activity, and refers to an activity of forming 3-acetylamino-4-hydroxybenzoic acid (3,4-AcAHBA) from 3-amino-4-hydroxybenzoic acid (3,4-AHBA) in relation with 3,4-AHBA. A phrase "modified to reduce the NhoA activity" refers to that the NhoA activity becomes lower than a specific activity in an unmodified strain, e.g., wild type Escherichia coli. The NhoA activity is preferably reduced to 50% or less, preferably 30% or less, and more desirably 10% or less per microbial cell compared with that in the unmodified strain. The "reduction" includes a case in which the activity disappears completely. In Escherichia coli of the present invention, it is only necessary that the NhoA activity is lower than that in the wild strain or the unmodified strain, but further accumulation of 3,4-AHBA is desirably enhanced compared with these strains. The phrase "modified to reduce the NhoA activity" corresponds to a case in which a molecular number of NhoA per cell is decreased and a case in which the NhoA activity per molecule is reduced, and the like. Specifically, the modification to reduce the NhoA activity can be introduced by conventional mutagenesis or gene engineering treatment. Examples of the mutagenesis may include irradiation with X ray or ultraviolet ray and treatment with a mutagenic agent such as N-methyl-N'-nitro-N-nitrosoguanidine. Examples of such modification may include introducing a mutation into a nhoA gene (including an expression regulatory region) on a chromosome or deleting a part of or all of the nhoA gene so that the NhoA activity can be reduced or disappear compared with non-mutated strains. Examples of methods for mutating or deleting the gene may include modification of the expression regulatory region such as a promoter sequence and Shine-Dalgarno (SD) sequence, introduction of a miss-sense mutation, a nonsense mutation or a frameshift mutation into an open reading frame, as well as partial deletion of the gene ( Levels of an activity and a reduced activity of a target enzyme can be confirmed by measuring an enzyme activity using a cell extract or a purified fraction therefrom obtained from a candidate microbial strain and comparing the activity with that of a wild strain or an unmodified strain. For example, the NhoA activity can be measured by the method described in Non-patent Literature 3. Escherichia coli modified to reduce the NhoA activity may include Escherichia coli inherently having the ability to produce 3,4-AHBA and Escherichia coli that does not inherently have the ability to produce 3,4-AHBA but has been given the ability to produce 3,4-AHBA. The ability to produce 3,4-AHBA can be given by a method described later. Appropriate strains can be used as Escherichia coli used in the present invention, and example thereof may include K12 strain (ATCC10798) or its substrains (e.g., BW25113 (CGSC7630), DH1 (ATCC33747), MG1655 (ATCC700926), W3110 (ATCC27325)), and B strain or its substrains (e.g., BL21 (ATCCBAA-1025), REL606 (CGSC12149)). Those designated with the CGSC number in the above strains can be obtained from The Coli Genetic Stock Center (http://cgsc.biology.yale.edu/). Those designated with the ATCC number in the above strains can be obtained from American Type Culture Collection (http://www.atcc.org/). NhoA may include a protein comprising an amino acid sequence having 70% or more, preferably 80% or more, more preferably 90% or more, still more preferably 95% or more, particularly preferably 98% or 99% or more identity to an amino acid sequence represented by SEQ ID NO:2 and having the NhoA activity. Also the nhoA gene may include one comprising a nucleotide sequence having 70% or more, preferably 80% or more, more preferably 90% or more, still more preferably 95% or more, particularly preferably 98% or 99% or more identity to a nucleotide sequence represented by SEQ ID NO:23 and encoding the protein having the NhoA activity. Homology (e.g., identity or similarity) between the amino acid sequences or between the nucleotide sequences can be determined by using algorithm BLAST by The nucleotide sequence of the nhoA gene is sometimes different depending on the strain of Escherichia coli. Examples of the protein encoded by the nhoA gene may include proteins comprising an amino acid sequence having one or several amino acid substitutions, deletions, insertions or additions at one or multiple positions in the amino acid sequence represented by SEQ ID NO:2 and having the NhoA activity. Here, "several" vary depending on types locations or the like of the amino acid residues in a three dimensional structure of a protein, but refer to preferably 1 to 50, more preferably 1 to 20, still more preferably 1 to 10 and particularly preferably 1 to 5. Such a substitution, deletion, insertion addition or the like includes those resulted from naturally occurring mutation (mutant or variant) based on individual difference of a microorganism having the nhoA gene. The nhoA gene may also be DNA that hybridizes with a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO:23 under the stringent condition and encodes the protein having the NhoA activity. Here, "the stringent condition" refers to a condition where a so-called specific hybrid is formed while a non-specific hybrid is not formed. One example is a condition where polynucleotides having high homology (e.g., identity or similarity), for example 70% or more, preferably 80% or more, more preferably 90% or more, still more preferably 95% or more, and particularly preferably 98% or more homology are hybridized each other while polynucleotides having lower homology than that are not hybridized each other. Specifically, such a condition may include hybridization in 6xSSC (sodium chloride/sodium citrate) at about 45°C followed by one or two or more washings in 0.2xSSC and 0.1% SDS at 50 to 65°C. The bacterium of the present invention may be a bacterium modified to increase the activity to produce 3-amino-4-hydroxybenzoic acid (3,4-AHBA) from dihydroxyacetone phosphate (DHAP) and aspartate semialdehyde (ASA). Such a modification can be accomplished by, for example, transforming the bacterium of the present invention with a recombinant vector incorporating DNA encoding a protein having the activity to form 3,4-AHBA from DHAP and ASA. The protein having the activity to form 3,4-AHBA from DHAP and ASA is not particularly limited as long as the protein contributes to the formation of 3,4-AHBA from DHAP and ASA, and includes, for example, proteins having an enzyme activity to catalyze the formation of a carbon-carbon bond between DHAP and ASA (hereinafter sometimes abbreviated as an "aldolase activity") and proteins having an enzyme activity to catalyze cyclization of a C7 compound obtained by forming the carbon-carbon bond between DHAP and ASA (hereinafter sometimes abbreviated as a 3-amino-4-hydroxybenzoic acid synthase activity). Hereinafter, both the above activities are sometimes referred to as the ability to biosynthesize 3,4-AHBA. A gene encoding the protein having the enzyme activity to catalyze the formation of the carbon-carbon bond between DHAP and ASA may include a griI gene or a griI gene homolog (both the griI gene and the griI gene homolog are sometimes together referred to as the griI gene simply) derived from Streptomyces griseus. The griI gene homolog refers to a gene that is derived from another microorganism, exhibits high homology to the above gene derived from Streptomyces griseus, and encodes a protein having the aldolase activity. Such a gene can be searched by BLAST search. Example thereof may include an nspI gene (SEQ ID NO:14 and 15) derived from Streptomyces murayamaensis, Fructose-bisphosphate aldolase (Accession no. YP_483282) and Fructose-bisphosphate aldolase (Accession no.YP_481172) derived from Frankia sp., Fructose-bisphosphate aldolase (http://www.sanger.ac.uk/cgi-bin/blast/submitblast/s_scabies) derived from Streptomyces scabies, fructose-bisphosphate aldolase (Accession no. Q39NQ9) derived from Burkholderia sp. 383, fructose-bisphosphate aldolase (Accession no. NP_247374) derived from Methanococcus jannaschii, and a dhn gene (Accession no. NC_000913) derived from Escherichia coli ( The gene encoding the protein having the enzyme activity to catalyze the cyclization of the C7 compound obtained by forming the carbon-carbon bond between DHAP and ASA may include a griH gene or a griH gene homolog (both the griH gene and the griH gene homolog are sometimes together referred to as the griH gene simply) derived from Streptomyces griseus. The griH gene homolog refers to a gene that is derived from another microorganism, exhibits the high homology to the gene derived from Streptomyces griseus, and encodes the protein having the 3-amino-4-hydrosybenzoic acid synthase activity. Such a gene can be searched by BLAST search. Example thereof may include an nspH gene (SEQ ID NO:16 and 17) derived from Streptomyces murayamaensis, 3-dehydroquinate synthase (Accession no. YP_483283) and 3-dehydroquinate synthase (Accession no. YP_481171) derived from Frankia sp., 3-dehydroquinate synthase (Accession no. YP_366552) and 3-dehydroquinate synthase (Accession no. YP_366553) derived from Burkholderia sp. 383, 3-dehydroquinate synthase (<http://www.sanger.ac.uk/cgi-bin/blast/submitblast/s_scabies>) derived from Streptomyces scabies, and 3-dehydroquinate synthase (Accession no. NP_248244) derived from Methanococcus jannaschii ( GriI and GriH or the griI gene and the griH gene derived from any organism can be used in the present invention. For example, they may be derived from microorganisms such as the bacteria or actinomycetes described above, and may preferably be derived from actinomycetes. Examples of actinomycetes may include microorganisms belonging to genus Streptomyces. Examples of the microorganisms belonging to genus Streptomyces may include Streptomyces griseus, Streptomyces murayamaensis, Streptomyces lividans, and Streptomyces scabies. GriI and GriH or the griI gene and the griH gene may be derived from the same microorganism or different microorganisms. A protein comprising an amino acid sequence having 70% or more, preferably 80% or more, more preferably 90% or more, still more preferably 95% or more, particularly preferably 98% or 99% or more identity to SEQ ID NO:5 or 14 that is an amino acid sequence of a protein encoded by the above griI gene and having the aldolase activity is desirable as the GriI homolog. Examples thereof may include SEQ ID NOS:9, 11, 13, 15, 17, 19, and 21 in Patent Literature 2. Also one comprising a nucleotide sequence having 70% or more, preferably 80% or more, more preferably 90% or more, still more preferably 95% or more, particularly preferably 98% or 99% or more identity to SEQ ID NO:6 or 15 that is a nucleotide sequence of the griI gene and encoding the protein having the aldolase activity is desirable as the griI gene homolog. Examples thereof may include SEQ ID NOS:8, 10, 12, 14, 16, 18 and 20 in Patent Literature 2. A protein comprising an amino acid sequence having 70% or more, preferably 80% or more, more preferably 90% or more, still more preferably 95% or more, particularly preferably 98% or 99% or more identity to SEQ ID NO:7 or 16 that is an amino acid sequence of a protein encoded by the above griH gene and having the 3-amino-4-hydroxybenzoic acid synthase activity is desirable as the GriH homolog. Examples thereof may include SEQ ID NOS:23, 25, 27, 29, 31, 33, and 35 in Patent Literature 2. Also one comprising a nucleotide sequence having 70% or more, preferably 80% or more, more preferably 90% or more, still more preferably 95% or more, particularly preferably 98% or 99% or more identity to SEQ ID NO:8 or 17 that is a nucleotide sequence of the griH gene and encoding the protein having the 3-amino-4-hydroxybenzoiic acid synthase activity is desirable as the griH gene homolog. Examples thereof may include SEQ ID NOS:22, 24, 26, 28, 30, 32, and 34 in Patent Literature 2. A position of an amino acid residue at which a mutation has no effect on an activity in an amino acid sequence is evident to a person skilled in the art, but a protein mutant may be made further with reference to sequence alignment. Specifically, those skilled in the art can (1) compare amino acid sequences of a plurality of homolog proteins, (2) demonstrate relatively conserved regions and relatively not conserved regions, then (3) predict a region capable of playing a functionally important role and a region incapable of playing a functionally important role from the relatively conserved regions and the relatively not conserved regions, respectively, and thus recognize correlativity of structures and functions. Patent Literature 2 has disclosed the alignment of the amino acid sequence of the above griI gene homolog ( The homology (e.g., identity or similarity) between the amino acid sequences and between the nucleotide sequences can be determined as described above. The nucleotide sequence of the griI gene or the griH gene may be different depending on species and microbial strain of the microorganism. Thus, the griI gene and the griH gene are only necessary to be able to enhance the ability to produce 3,4-AHBA in Escherichia coli by expressing them in Escherichia coli, e.g., augmenting their expression. For example, a protein comprising one or several amino acid substitutions, deletions, insertions additions or the like at one or multiple positions in the amino acid sequence of the protein encoded by the griI gene (SEQ ID NO:5 or 14) and having the aldolase activity is desirable as the protein encoded by the griI gene. Examples thereof may include SEQ ID NOS:9, 11, 13, 15, 17, 19, and 21 in Patent Literature 2. A protein comprising one or several amino acid substitutions, deletions, insertions additions or the like at one or multiple positions in the amino acid sequence of the protein encoded by the griH gene (SEQ ID NO:7 or 16) and having the 3-amino-4-hydroxybenzoic acid synthase activity is desirable as the protein encoded by the griH gene. Examples thereof may include SEQ ID NOS:23, 25, 27, 29. 31, 33, and 35 in Patent Literature 2. Here, "several" vary depending on types or locations of the amino acid residues in a three dimensional structure of a protein, but refer to preferably 1 to 50, more preferably 1 to 20, still more preferably 1 to 10 and particularly preferably 1 to 5. Such an amino acid substitution, deletion, insertion addition or the like includes those resulted from naturally occurring mutation (mutant or variant) based on individual difference or species difference of the microorganism having the the griI gene or the griH gene. The substitution is preferably the conservative substitution that is neutral substitution in which a function is not changed. The conservative substitution is as described above. Further, degeneracy of the griI gene and the griH gene varies depending on a host to which such a gene is introduced. Thus, codons may be replaced with codons available in Escherichia coli. Likewise, the griI gene and the griH gene may be genes encoding proteins extended or truncated on an N terminal side and/or a C terminal side as long as the gene has a function to enhance the ability to produce 3,4-AHBA in Escherichia coli. For example, a length of extended or truncated residues is 50 or less, preferably 20 or less, more preferably 10 or less and particularly preferably 5 or less of amino acid residues. More specifically, the gene may be a gene encoding a protein in which 50 to 5 amino acid residues on the N terminal side or 50 to 5 amino acid residues on the C terminal side have been extended or truncated. Such a gene that is homologous to the griI gene or the griH gene can be acquired by, for example, modifying the gene encoding an amino acid sequence by site-specific mutagenesis so that an amino acid residue at a particular position of the encoded protein can comprise the substitution, deletion, insertion or addition. Such a homologous gene can also be acquired by conventionally known mutation treatments as follows. A method of treating the griI gene or the griH gene with hydroxylamine and the like in vitro and a method of treating a microorganism carrying the gene with ultraviolet ray or a mutating agent such as N-methyl-N'-nitro-N-nitrosoguanidine (NTG) or ethyl methanesulfonate (EMS) generally used for the mutation treatment, error prone PCR ( The griI gene can also be DNA that hybridizes with a nucleotide sequence complementary to a nucleotide sequence of the griI gene or its homolog gene (e.g., SEQ ID NO:6 or 15, or SEQ ID NO:8, 10, 12, 14, 16, 18 or 20 in Patent Literature 2) under the stringent condition and encodes the protein having the aldolase activity. The griH gene can also be DNA that hybridizes with a nucleotide sequence complementary to a nucleotide sequence of the griH gene or its homolog gene (e.g., SEQ ID NO:8 or 17, or SEQ ID NO:22, 24, 26, 28, 30, 32 or 34 in Patent Literature 2) under the stringent condition and encodes the protein having the 3-amino-4-hydroxybenzoic acid synthase activity. The "stringent condition" is the same as described above. The descriptions concerning the above gene homologs and the conservative substitution are applied to the other genes described herein in the same manner. Whether these griI gene and griH gene and the homolog genes thereof encode or not the protein that enhances the ability to produce 3,4-AHBA can be confirmed by introducing these genes into a bacterium and the like having a gene encoding mutated aspartokinase in which feedback inhibition is canceled and examining whether the activity of forming 3,4-AHBA is enhanced or not. In such a case, the effect can be verified more clearly by quantifying 3,4-AHBA using reverse phase chromatography according to, for example, A recombinant vector that can be used in the present invention can be obtained by introducing a desired gene into an expression vector. For example, when both the griI and the griH are used, they may be carried in a separate recombinant vector, respectively to use for transformation, or may be linked via an appropriate spacer and carried in the same recombinant vector to use for the transformation, as long as they are contained in a transformant in an expressible state, respectively. The griI gene and the griH gene may be derived from the same microorganism or different microorganisms. When the griI gene and the griH gene are derived from the same microorganism and located in close proximity on a chromosome, a DNA fragment including both griI and griH may be cut out and carried in a vector. The recombinant vector used in the present invention generally has a promoter, the aforementioned DNA of the present invention, e.g., griI and griH, and regulatory regions (operator and terminator) necessary for expression of the genes in Escherichia coli at appropriate positions so that they can work. The expression vector that can be used as the recombinant vector is not particularly limited, is only necessary to be able to work in Escherichia coli, and may be those which self-replicates out of a chromosome such as a plasmid or may be integrated into a chromosome in a bacterium. Specifically, examples of the expression vector may include pSTV (e.g., pSTV28), pUC (e.g., pUC18, pUC19), pBR (e.g., pBR322), pHSG (e.g., pHSG298, pHSG299, pHSG399, pHSG398), pACYC (e.g., pACYC177, pACYC184), pMW (e.g., pMW118, pMW119, pMW218, pMW219), pQE (e.g., pQE) and derivatives thereof. A promoter that can be used in the present invention is not particularly limited, and a promoter generally used for production of a foreign protein in Escherichia coli can be used. Examples thereof may include potent promoters such as a T7 promoter, a lac promoter, a trp promoter, a trc promoter, a tac promoter, a PR promoter and PL promoter of a lambda phage, a T5 promoter, and the like. The bacterium of the present invention is not particularly limited as long as this is Escherichia coli modified to have the ability to produce 3-amino-4-hydroxybenzoic acid and to reduce the activity of N-hydroxyarylamine O-acetyltransferase (NhoA), and is preferably a transformant. The transformant of the present invention is preferably obtained by being transformed with a recombinant vector in which DNA encoding a protein having the activity of forming 3-amino-4-hydroxybenzoic acid from dihydroxyacetone phosphate and aspartate semialdehyde has been introduced. Escherichia coli used as a host is preferably a strain that can efficiently supply dihydroxyacetone phosphate and aspartate semialdehyde that are the substrates for biosynthesis of a 3-amino-4-hydroxybenzoic acid-type compound. Escherichia coli has aspartokinase III (AKIII) that is a non-coupled enzyme and works alone. AKIII in Escherichia coli originally undergoes feedback inhibition by lysine. Escherichia coli of the present invention preferably has an AKIII gene having a mutation capable of canceling the feedback inhibition by lysine. The mutation capable of canceling the feedback inhibition by the amino acid such as lysine has been reported for aspartokinase derived from various microorganisms such as Escherichia coli, Corynebacterium glutamicum, and Serratia marcescens. For example, the mutation of glutamic acid to lysine at position 250 (E250K), the mutation of methionine to isoleucine at position 318 (M318I), the mutation of threonine to methionine at position 344 (T344M), the mutation of serine to leucine at position 345 (S345L), and the mutation of threonine to isoleucine at position 352 (T352I) have been reported as the mutation capable of canceling the feedback inhibition by lysine in AKIII in Escherichia coli (see e.g., The expression of a pyruvate carboxylase gene may further be augmented in Escherichia coli having the mutated AKIII in which the feedback inhibition was canceled. According to methods known in the art, Escherichia coli can be transformed with a recombinant vector incorporating DNA encoding a protein having the activity of forming 3-amino-4-hydroxybenzoic acid from dihydroxyacetone phosphate and aspartate semialdehyde. For example, a protoplast method ( The present invention also provides a method for producing a 3-amino-4-hydroxybenzoic acid-type compound, comprising a step of culturing the bacterium of the present invention. The 3-amino-4-hydroxybenzoic acid-type compound in the present invention includes 3-amino-4-hydroxybenzoic acid (hereinafter sometimes abbreviated as "3,4-AHBA") having the following structure as well as a derivative and a salt thereof. In the derivative of 3-amino-4-hydroxybenzoic acid, (1) at least one group selected from the group consisting of a carboxyl group at position 1, an amino group at position 3 and a hydroxyl group at position 4 is derivatized, (2) the carboxyl group at position 1, the amino group at position 3 and the hydroxyl group at position 4 are kept and a hydrogen atom on at least one carbon atom selected from carbon atoms at positions 2, 5 and 6 is substituted with other atom or group, or (3) (1) and (2) are combined. Examples of the other atom or group in (2) above may include halogen atoms (e.g., a fluorine atom, a bromine atom, a chlorine atom, an iodine atom), alkyl groups (e.g., alkyl groups having 1 to 6 carbon atoms such as methyl, ethyl, propyl, butyl, pentyl, and hexyl), a hydroxyl group, an alkyloxy group (the alkyl moiety is the same as described above), an amino group, a mono- or di-alkylamino group (the alkyl moiety is the same as described above), a cyano group, a nitro group, a sulfonyl group, and a carboxyl group. Specifically, examples of the derivative in (1) above may include derivatives in which the carboxyl group at position 1 is derivatized (e.g., 3-amino-4-hydroxybenzaldehyde in which the carboxyl group in 3-amino-4-hydroxybenzoic acid is aldehydated), derivatives in which the amino group at position 3 is derivatized with the group such as the above alkyl group (e.g., 3-alkylamino derivatives), and derivatives in which the hydroxyl group at position 4 is derivatized with the group such as the above alkyl group (e.g., 4-mono- or di-alkylamino derivatives). Basic salts such as alkali metal (e.g., sodium, potassium, lithium) salts and alkali earth metal (e.g., calcium, magnesium) salts of carboxylic acid, and acid addition salts such as hydrochloride salts, sulfate salts, lead nitrate and phosphate salts are exemplified as salts. The 3-amino-4-hydroxybenzoic acid-type compound can be produced by culturing the bacterium of the present invention and recovering the 3-amino-4-hydroxybenzoic acid-type compound produced in the medium. The medium for culturing the bacterium of the present invention is not particularly limited as long as Escherichia coli is grown, and the bacterium can be cultured according to methods publicly known in the art. For example, the bacterium can be cultured in the ordinary medium containing a carbon source, a nitrogen source, and inorganic ions. Organic trace nutrients such as vitamins and amino acids may be added if necessary in order to obtain higher proliferation. A cultivation temperature is generally 25 to 42°C, and it is desirable to control pH to 5 to 8. A cultivation time period is generally 20 to 90 hours. It is desirable to perform the cultivation of the bacterium of the present invention under an condition that controls oxygen supply. Specifically, it is desirable to keep oxygen at 2.0 ppm or less when bacterial growth is changed to a logarithmic growth phase. A recovery method used in steps of recovering and purifying the 3-amino-4-hydroxybenzoic acid-type compound from the culture medium can be appropriately selected from publicly known methods. For example, it is preferable to recover from a culture medium supernatant obtained by removing microbial cells by centrifugation or membrane filtration after adjusting pH of the culture medium to acidic pH at which solubility of the 3-amino-4-hydroxybenzoic acid-type compound is high. The recovery method of 3-amino-4-hydroxybenzoic acid from the culture medium supernatant in which the microbial cells have been removed may include purification by a porous adsorbent, crystallization and precipitation. The porous adsorbent used in the present invention is a porous solid adsorbent having a large surface area, and specifically includes hydrophilic adsorbents typified by silica gel, alumina, zeolite, bauxite, magnesia, activated white earth, acrylic synthetic adsorbents, and the like, and hydrophobic adsorbents typified by vegetable charcoal, bone charcoal, activated charcoal and aromatic synthetic adsorbents. In the present invention, any adsorbent can be used without particular limitation as long as a purity of the 3-amino-4-hydroxybenzoic acid-type compound can be enhanced by adsorbing the impurities. In this regard, however, the impurities adsorbed by the porous adsorbent abundantly contain aromatic compounds mainly produced in the process of biochemical synthesis. Thus, the hydrophobic adsorbent typified by the activated charcoal and the aromatic synthetic adsorbent to which these compounds easily adsorb is suitably used in the present invention. These hydrophobic adsorbents may be used alone or in combination of two or more. When the activated charcoal is used, its raw material is not particularly limited, and may include, but not particulary limited, plant raw materials such as wood powder and palm shell, coal/petroleum-based raw materials such as smokeless coal, petroleum pitch and cokes, synthetic resin-based raw materials such as acrylic resins, phenol resins, epoxy resins and polyester resins. Shapes of the activated charcoal are powder, grain and fibrous, and secondary processed articles such as filters and cartridges, and that easily handled may be appropriately selected. Meanwhile, when the aromatic synthetic adsorbent is used, the raw material thereof is not particularly limited, and for example, the porous resins such as 1) unsubstituted aromatic resins, 2) aromatic resins having a hydrophobic substituent(s), and 3) aromatic resins obtained by giving a special treatment to the unsubstituted aromatic resins can be used. Specific compounds may include, for example, styrene- and divinylbenzene-based resins. As mentioned above, an objective of contacting the 3-amino-4-hydroxybenzoic acid-type compound in the culture medium with the porous adsorbent is to adsorb the impurities to the porous adsorbent and to improve the purity of the 3-amino-4-hydroxybenzoic acid-type compound. However, 3-amino-4-hydroxybenzoic acid which is an objective product in no small part is adsorbed together with the impurities to the porous adsorbent in some cases. Thus, it is also possible to isolate and recover the 3-amino-4-hydroxybenzoic acid-type compound by contacting the 3-amino-4-hydroxybenzoic acid-type compound in the culture medium to the porous adsorbent, then contacting the porous adsorbent with a polar organic solvent to detach and dissolve the 3-amino-4-hydroxybenzoic acid-type compound in the polar organic solvent. The polar organic solvent used in the present invention refers to the organic solvent composed of polar molecules having a high dielectric constant, and can be used without particular limitation as long as the 3-amino-4-hydroxybenzoic acid-type compound can be detached from the porous adsorbent and the 3-amino-4-hydroxybenzoic acid-type compound can be dissolved in the polar organic solvent. The polar organic solvent may be used alone or in combination of two or more at a desired combination ratio. The crystallization or the precipitation in the present invention refers to a manipulation to produce a crystal or a precipitate by evaporating the solvent in which an objective substance is dissolved to concentrate, or lowering the temperature, or keeping the concentration higher than a saturation solubility by adding a poor solvent to the solvent in which an objective substance is dissolved, and is not particularly limited including conventionally and publicly known methods. The produced crystal or precipitate can be separated by precipitation, filtration, centrifugation or the like. The present invention also provides a method of producing a polymer comprising a 3-amino-4-hydroxybenzoic acid-type compound as a component. The production method of a polymer according to the present invention comprises a step of polymerizing a 3-amino-4-hydroxybenzoic acid-type compound as at least one constituent of the polymer. For example, the 3-amino-4-hydroxybenzoic acid-type compound that its purity has been improved from the culture medium of the bacterium of the present invention by using the porous adsorbent or by the crystallization, the precipitation or the like is polymerized by condensation polymerization in a non-oxidizing solvent acid such as methanesulfonic acid or polyphosphoric acid at high temperature (e.g., It has been reported that arylamine N-acetyltransferase (convertible term: NatA; NCBI accession ID:BAF46971.1) catalyzes an N-acetylation reaction of 3,4-AHBA in Streptomyces griseus IFO13350 strain, and an amino acid sequence of NatA has been known publicly [ The amino acid sequence of NatA is shown in SEQ ID NO:1. In order to search an enzyme having the same function as that of NatA, sequences having the homology to the sequence of NatA were searched from genomic information of Escherichia coli K-12 strain. As a result of the search utilizing the published database (EcoCyc, Escherichia coli BW25113 ΔnhoA (same strain: JW1458, Keio Collection) was used as a strain having a deletion of a gene which codes NhoA (convertible term: nhoA, GenBank accession No.: NC_000913.2, GI: 947251). Escherichia coli BW25113 ΔnhoA strain is a strain obtained by deleting the nhoA gene in Escherichia coli BW25113 strain ( The ability to convert 3,4-AHBA in Escherichia coli BW25113 ΔnhoA strain and BW25113 strain was calculated according to the following procedure. Microbial cells of each strain were uniformly applied onto an LB plate, and cultured at 37°C for 24 hours. One loopful of the microbial cells from the resulting plate was inoculated in 4 mL of MS glucose/3,4-AHBA medium in a test tube, and cultured at 30°C for 30 hours on a reciprocal shaking cultivation apparatus. A composition of the MS glucose/3,4-AHBA medium is as described in the following Table 1. A pH value of the medium was adjusted to 7.0 with KOH, and the medium was autoclaved at 120°C for 20 minutes. And, glucose and MgSO4·7H2O were mixed and sterilized separately. CaCO3 was added after dry heat sterilization. 3,4-AHBA was dissolved at 20 g/L in distilled water, then adjusted to pH 7.0 with KOH, sterilized through a filter, and subsequently added at a final concentration of 2.0 g/L. After completion of the cultivation, an optical density (OD) value of the culture medium was measured using a spectrophotometer (HITACHI U-2900) at 600 nm. 3,4-AHBA in a culture supernatant was separated using reverse phase column chromatography, and its concentration was quantified ( As a result, the concentration of 3,4-AHBA in the culture supernatant after the cultivation of Escherichia coli BW25113 strain was decreased to 30% of an initial concentration. On the other hand, decrease of the 3,4-AHBA concentration in the culture supernatant after the cultivation in Escherichia coli BW25113 ΔnhoA strain was around 10%. Therefore, it was strongly suggested that NhoA catalyzed the conversion reaction of 3,4-AHBA. Charts of the reverse phase column chromatography for the culture supernatant of Escherichia coli BW25113 strain, the culture supernatant of Escherichia coli BW25113 ΔnhoA strain, and a 3,4-AHBA standard preparation (supplied from Tokyo Chemical Industry CO., Ltd. , Cat. No.:A0859) were shown in A molecular weight of a product converted from 3,4-AHBA (R.T., 9.5 minutes) described in Example 1(2) and contained in the culture supernatant after the cultivation of BW25113 strain was identified by LC/MS. An analysis condition is as follows.
As a result of the analysis, an m/z value of the converted product (R.T., 9.5 minutes) was 195.1, which was consistent with a calculated m/z value of an acetylated product of 3,4-AHBA (195.1). Hereinafter, this converted product (R.T., 9.5 minutes) is referred to as 3,4-AcAHBA. Subsequently, an effect of nhoA deletion on accumulation of 3,4-AHBA was verified in 3,4-AHBA producing bacteria. First, a plasmid pSTV28-Ptac-Ttrp for expression was constructed for giving an ability to produce 3,4-AHBA. To begin with, a DNA fragment comprising a tac promoter (convertible term: Ptac) region ( It has been already known that synthesis of 3,4-AHBA is catalyzed by a 3,4-AHBA synthetase group consisting of aldolase (convertible term: SGR_4249, GriI) and 3,4-AHBA synthase (convertible term: SGR_4248, GriH) in Streptomyces griseus IFO13350 strain, and sequences of the genes encoding these enzymes have been known publicly ( In order to efficiently express the griI gene and the griH gene in Escherichia coli, a sequence was designed so as to correspond to the codon usage in Escherichia coli by changing the sequences of the griI gene and the griH gene and to express as an operon, and this sequence was designated as EcGriIH. A DNA fragment was chemically synthesized by adding an EcoRI restriction enzyme recognition sequence to the 5' terminus and a HindIII restriction enzyme recognition sequence to the 3' terminus of EcGriIH (its sequence is shown in SEQ ID NO:9). EcGriIH, both termini of which the restriction enzyme recognition sequence had been added to was digested with EcoRI and HindIII, and then cloned into pUC57 (supplied from GenScript) digested with the same enzymes. The resulting vector was designated as pUC57-EcGri. A full length sequence of pUC57-EcGri is shown in SEQ ID NO:10. An expression plasmid for expressing the griI gene and the griH gene in Escherichia coli was constructed by the following procedure. PCR was performed with pUC57-EcGri as a template using a synthesized oligonucleotide represented by SEQ ID NO:11 and further a synthesized oligonucleotide represented by SEQ ID NO:12 as primers and using PrimeStar GXL polymerase (supplied from Takara Bio Inc.). A reaction solution was prepared according to a composition attached to the kit, and a reaction at 98°C for 10 seconds, 55°C for 15 seconds and 68°C for 150 seconds was performed in 30 cycles. As a result, a PCR product of about 2.1 kbp containing the EcGriIH gene fragment was obtained. Subsequently, the purified EcGriIH gene fragment and pSTV28-Ptac-Ttrp digested with SmaI were ligated using In-Fusion HD Cloning Kit (supplied from Clontech). The resulting plasmid for expressing the griIH gene was designated as pSTV28-EcGri. A full length sequence of pSTV28-EcGri is shown in SEQ ID NO:13. Competent cells of Escherichia coli BW25113 strain and BW25113 ΔnhoA strain were prepared, subsequently pSTV28-EcGri was introduced thereto by electroporation, then the cells were uniformly applied onto an LB plate containing 30 mg/L of chloramphenicol, and cultured at 37°C for 24 hours. Transformants that were resistant to chloramphenicol were obtained from the resulting plate. A strain in which pSTV28-EcGri had been introduced into BW25113 strain was designated as BW25113/pSTV28-EcGri strain, and a strain in which pSTV28-EcGri had been introduced into Escherichia coli BW25113 ΔnhoA strain was designated as BW25113ΔnhoA/pSTV28-EcGri strain. Microbial cells of BW25113ΔnhoA/pSTV28-EcGri strain and BW25113/pSTV28-EcGri strain were uniformly applied onto an LB plate containing 30 mg/L of chloramphenicol, and cultured at 37°C for 24 hours. One loopful of the microbial cells from the resulting plate was inoculated in 4 mL of MS glucose/Asp medium containing 30 mg/L of chloramphenicol and 0.1 mM isopropyl-β-thiogalactopyranoside in a test tube, and cultured at 30°C for 48 hours on the reciprocal shaking cultivation apparatus. A composition of the MS glucose/Asp medium is as described in the following Table 3. [Table 3] A pH value of the medium was adjusted to 7.0 with KOH, and the medium was autoclaved at 120°C for 20 minutes. But, glucose and MgSO4·7H2O were mixed and sterilized separately. CaCO3 was added after dry heat sterilization. After the cultivation, the OD value of the culture medium at 600 nm was measured using the spectrophotometer (HITACHI U-2900). 3,4-AHBA and 3,4-AcAHBA were separated using the reverse phase column chromatography, and their concentrations were quantified ( [Table 4] It has been already known that the synthesis of 3,4-AHBA is catalyzed by a 3,4-AHBA synthetase group consisting of aldolase (convertible term: NspI; NCBI accession ID: BAJ08171.1) and 3,4-AHBA synthase (convertible term: NspH; NCBI accession ID: BAJ08172.1) in Streptomyces murayamaensis ( In order to efficiently express the nspI gene and the nspH gene in Escherichia coli, a sequence was designed so as to correspond to the codon usage in Escherichia coli by changing the sequences of the nspI gene and the nspH gene and to express as an operon, and this sequence was designated as EcNspIH. A DNA fragment was chemically synthesized by adding an EcoRI restriction enzyme recognition sequence to the 5' terminus and a HindIII restriction enzyme recognition sequence to the 3' terminus of EcNspIH (its sequence is shown in SEQ ID NO:18). EcNspIH, both termini of which the restriction enzyme recognition sequence had been added to was digested with EcoRI and HindIII, and then cloned into pUC57 (supplied from GenScript) digested with the same restriction enzymes. The resulting vector was designated as pUC57-EcNsp. A full length sequence of pUC57-EcNsp is shown in SEQ ID NO:19. An expression plasmid for expressing the nspI gene and the nspH gene in Escherichia coli was constructed by the following procedure. PCR was performed with pUC57-EcNsp as a template using a synthesized oligonucleotide represented by SEQ ID NO:20 and further a synthesized oligonucleotide represented by SEQ ID NO:21 as primers and using PrimeStar GXL polymerase (supplied from Takara Bio Inc.). A reaction solution was prepared according to a composition attached to the kit, and a reaction at 98°C for 10 seconds, 55°C for 15 seconds and 68°C for 150 seconds was performed in 30 cycles. As a result, a PCR product of about 2.1 kbp containing the EcNspIH gene fragment was obtained. Subsequently, the purified EcNspIH gene fragment and pSTV28-Ptac-Ttrp digested with SmaI (described in Example 2) were ligated using In-Fusion HD Cloning Kit (supplied from Clontech). The resulting plasmid for expressing the nspIH gene was designated as pSTV28-EcNsp. A full length sequence of pSTV28-EcNsp is shown in SEQ ID NO:22. Competent cells of Escherichia coli BW25113 strain and BW25113 ΔnhoA strain were prepared, subsequently pSTV28-EcNsp was introduced thereto by electroporation, then the cells were uniformly applied onto an LB plate containing 30 mg/L of chloramphenicol, and cultured at 37°C for 24 hours. Transformants that were resistant to chloramphenicol were obtained from the resulting plate. A strain in which pSTV28-EcNsp had been introduced into BW25113 strain was designated as BW25113/pSTV28-EcNsp strain, and a strain in which pSTV28-EcNsp had been introduced into Escherichia coli BW25113 ΔnhoA strain was designated as BW25113ΔnhoA/pSTV28-EcNsp strain. Microbial cells of BW25113 /pSTV28-EcNsp strain and BW25113ΔnhoA /pSTV28-EcNsp strain were uniformly applied onto an LB plate containing 30 mg/L of chloramphenicol, and cultured at 37°C for 24 hours. One loopful of the microbial cells from the resulting plate was inoculated in 4 mL of MS glucose/Asp medium containing 30 mg/L of chloramphenicol and 0.1 mM isopropyl-β-thiogalactopyranoside and described in Table 3 in a test tube, and cultured at 30°C for 48 hours on the reciprocal shaking cultivation apparatus. After the cultivation, the OD value of the culture medium at 600 nm was measured using the spectrophotometer (HITACHI U-2900). 3,4-AHBA and 3,4-AcAHBA were separated using the reverse phase column chromatography, and their concentrations were quantified ( [Table 5] According to the present invention, it is possible to conveniently and inexpensively produce an amino-hydroxybenzoic acid-type compound that is useful as an intermediate of dyes, agricultural chemicals, pharmaceuticals and other organic synthesized articles and as a monomer for polybenzoxazole. Thus, for example, polybenzoxazole (PBO) is obtained by polymerizing 3-amino-4-hydroxybenzoic acid obtained by the present invention, thereby enabling to inexpensively provide PBO fibers and PBO films having high strength, high elastic modulus and high resistance to heat. It is also possible to produce a 3-amino-4-hydroxybenzoic acid-type compound that is a raw material by biosynthesis. Thus, the method of the present invention is a process with low environmental load and an environmentally-friendly production method. |
||||||
